Developer docs
API playgroundTry for free, no card

Search company profiles

VelosBio

Full company profile

uuid0000tan

Namestring
VelosBio
Websiteurl
velosbio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

VelosBio is a clinical-stage biotechnology company founded in 2017 and headquartered in San Diego, California. The company is focused on developing next-generation antibody-drug conjugates (ADCs) intended to treat hematological cancers, a therapeutic modality that combines targeted antibody recognition with cytotoxic payloads to selectively eliminate malignant cells while limiting off-target toxicity. VelosBio operates with a focused team of 11-50 employees and is led by founder and CEO Dave Johnson. As a private, pre-commercial oncology company, VelosBio's operations center on ADC discovery and clinical translation rather than marketed product revenue.

The company's funding profile reflects strong institutional validation of its ADC platform. Through three disclosed rounds, VelosBio has raised approximately $202.7 million in aggregate: a $7.7 million round in February 2018, a $58 million Series B in October 2018 led by Arix Bioscience and Sofinnova Investments with participation from Chiesi Ventures, Decheng Capital, Pappas Ventures, and Takeda Ventures, and a $137 million Series B in July 2020 co-led by Matrix Capital Management and Surveyor Capital. The 2020 round featured a deep syndicate of crossover and late-stage investors — including Takeda Ventures, T. Rowe Price, Wellington Management, OrbiMed, Viking Global Investors, Foresite Capital, Janus Henderson Investors, Logos Capital, Cormorant, Adage Capital, Farallon Capital, Decheng Capital, Pappas Capital, Mesa Verde Venture Partners, Global Source Ventures, and Venrock — consistent with a clinical-stage biotech preparing for either accelerated pipeline advancement or strategic transaction activity.

Because VelosBio remains pre-commercial, the business model is venture-funded R&D rather than product commercialization. No pricing model, customer list, partnership economics, or commercial revenue disclosure is available in the source material. The investor base — particularly the breadth of crossover participation in 2020 — is the principal evidence of platform credibility in the absence of commercial-stage data.

Short descriptiontext

VelosBio is a privately held, San Diego-based clinical-stage oncology company founded in 2017 that develops novel antibody-drug conjugates (ADCs) targeting hematological cancers, led by founder-CEO Dave Johnson and backed by approximately $202.7M in venture funding.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
antibody-drug conjugates, oncology therapeutics, haematological cancer treatment, ADC drug development, cancer biopharmaceuticals
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Therapeutics
No data
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

VelosBio is a clinical-stage biopharmaceutical company developing novel antibody-drug conjugates (ADCs) for the treatment of haematological cancers. The company builds next-generation oncology therapeutics that combine tumour-targeting antibodies with cytotoxic payloads to selectively destroy cancer cells.

Differentiator
Functional benefit
Problem solved
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing antibody-drug conjugates for haematological and solid tumours, with an FDA-approved ADC (Zynlonta) for DLBCL. Most directly comparable to VelosBio given its ADC focus on blood cancers and similar clinical-stage profile.

TypeDirect peer
Description

Pioneer in ADC technology with multiple approved ADC products; acquired by AbbVie in 2024. Directly comparable ADC platform peer with deeper pipeline and commercialisation track record, validating the ADC modality VelosBio pursues.

TypeDirect peer
Description

Leading commercial-stage ADC company (Adcetris, Padcev, Tukysa) acquired by Pfizer in 2023. Direct ADC peer serving haematology and solid tumour indications with proven linker-payload chemistry relevant to VelosBio's approach.

TypeDirect peer
Description

Clinical-stage ADC biotech developing novel payload and linker chemistries (Dolasynthen, Immunosynthen platforms). Comparable as a platform ADC peer of similar size and stage, though focused on solid tumours.

TypeDirect peer
Description

German ADC biotech pioneering amanitin-based payloads with multiple partnered programmes. Comparable as a clinical-stage ADC platform company with proprietary payload chemistry targeting haematology and solid tumours.

TypeEmerging player
Description

Clinical-stage ADC and immuno-oncology company developing ADCs for both solid and haematological malignancies. Smaller-scale emerging player comparable in modality focus though broader in indication scope.

TypeEmerging player
Description

Clinical-stage biotech developing immune-stimulating ADCs (ISACs) for oncology. Comparable as an emerging ADC platform peer, though differentiated by its immune-agonist payload approach.

TypeBroad incumbent
Description

Global pharma leader in ADCs (Enhertu, Datroway) with extensive ADC pipeline and major partnerships with AstraZeneca. Sets the competitive benchmark for ADC platform economics VelosBio is competing against.

TypeBroad incumbent
Description

Top-tier oncology pharma with a deep ADC portfolio via the Daiichi Sankyo alliance (Enhertu, Datroway). Broad incumbent that competes with VelosBio's target indications and could be a potential strategic acquirer of ADC assets.

TypeBroad incumbent
Description

Owns Trodelvy (sacituzumab govitecan) via its Immunomedics acquisition, anchoring a growing ADC franchise in oncology. Broad incumbent actively building ADC capability through M&A — a plausible acquirer profile for an ADC-focused biotech like VelosBio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VelosBio

Oncology Therapeuticsvelosbio.com

VelosBio is a privately held, San Diego-based clinical-stage oncology company founded in 2017 that develops novel antibody-drug conjugates (ADCs) targeting hematological cancers, led by founder-CEO Dave Johnson and backed by approximately $202.7M in venture funding.

What VelosBio does

VelosBio is a clinical-stage biotechnology company founded in 2017 and headquartered in San Diego, California. The company is focused on developing next-generation antibody-drug conjugates (ADCs) intended to treat hematological cancers, a therapeutic modality that combines targeted antibody recognition with cytotoxic payloads to selectively eliminate malignant cells while limiting off-target toxicity. VelosBio operates with a focused team of 11-50 employees and is led by founder and CEO Dave Johnson. As a private, pre-commercial oncology company, VelosBio's operations center on ADC discovery and clinical translation rather than marketed product revenue.

The company's funding profile reflects strong institutional validation of its ADC platform. Through three disclosed rounds, VelosBio has raised approximately $202.7 million in aggregate: a $7.7 million round in February 2018, a $58 million Series B in October 2018 led by Arix Bioscience and Sofinnova Investments with participation from Chiesi Ventures, Decheng Capital, Pappas Ventures, and Takeda Ventures, and a $137 million Series B in July 2020 co-led by Matrix Capital Management and Surveyor Capital. The 2020 round featured a deep syndicate of crossover and late-stage investors — including Takeda Ventures, T. Rowe Price, Wellington Management, OrbiMed, Viking Global Investors, Foresite Capital, Janus Henderson Investors, Logos Capital, Cormorant, Adage Capital, Farallon Capital, Decheng Capital, Pappas Capital, Mesa Verde Venture Partners, Global Source Ventures, and Venrock — consistent with a clinical-stage biotech preparing for either accelerated pipeline advancement or strategic transaction activity.

Because VelosBio remains pre-commercial, the business model is venture-funded R&D rather than product commercialization. No pricing model, customer list, partnership economics, or commercial revenue disclosure is available in the source material. The investor base — particularly the breadth of crossover participation in 2020 — is the principal evidence of platform credibility in the absence of commercial-stage data.

VelosBio firmographics

Firmographics
Name
VelosBio
Website
https://velosbio.com
Company type
Private
Founded year
2017
Headcount range
11–50 employees
Short description
VelosBio is a privately held, San Diego-based clinical-stage oncology company founded in 2017 that develops novel antibody-drug conjugates (ADCs) targeting hematological cancers, led by founder-CEO Dave Johnson and backed by approximately $202.7M in venture funding.
Ownership category
akta.pro rank

VelosBio industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody-drug conjugates
  • Oncology therapeutics
  • Haematological cancer treatment
  • ADC drug development
  • Cancer biopharmaceuticals

Where VelosBio is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

VelosBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

VelosBio product offering

Product offering

Core offering

VelosBio is a clinical-stage biopharmaceutical company developing novel antibody-drug conjugates (ADCs) for the treatment of haematological cancers. The company builds next-generation oncology therapeutics that combine tumour-targeting antibodies with cytotoxic payloads to selectively destroy cancer cells.

Differentiator

Problem solved

Functional benefit

Companies that use VelosBio

Customer profile

Ideal customer profiles1 record

VelosBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

VelosBio partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights4 records

VelosBio competitors and assessment

Company assessment

Direct peers

  • ADC Therapeutics: Clinical-stage biotech developing antibody-drug conjugates for haematological and solid tumours, with an FDA-approved ADC (Zynlonta) for DLBCL. Most directly comparable to VelosBio given its ADC focus on blood cancers and similar clinical-stage profile.
  • ImmunoGen: Pioneer in ADC technology with multiple approved ADC products; acquired by AbbVie in 2024. Directly comparable ADC platform peer with deeper pipeline and commercialisation track record, validating the ADC modality VelosBio pursues.
  • Seagen: Leading commercial-stage ADC company (Adcetris, Padcev, Tukysa) acquired by Pfizer in 2023. Direct ADC peer serving haematology and solid tumour indications with proven linker-payload chemistry relevant to VelosBio's approach.
  • Mersana Therapeutics: Clinical-stage ADC biotech developing novel payload and linker chemistries (Dolasynthen, Immunosynthen platforms). Comparable as a platform ADC peer of similar size and stage, though focused on solid tumours.
  • Heidelberg Pharma: German ADC biotech pioneering amanitin-based payloads with multiple partnered programmes. Comparable as a clinical-stage ADC platform company with proprietary payload chemistry targeting haematology and solid tumours.

Emerging players

  • Pyxis Oncology: Clinical-stage ADC and immuno-oncology company developing ADCs for both solid and haematological malignancies. Smaller-scale emerging player comparable in modality focus though broader in indication scope.
  • Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating ADCs (ISACs) for oncology. Comparable as an emerging ADC platform peer, though differentiated by its immune-agonist payload approach.

Broad incumbents

  • Daiichi Sankyo: Global pharma leader in ADCs (Enhertu, Datroway) with extensive ADC pipeline and major partnerships with AstraZeneca. Sets the competitive benchmark for ADC platform economics VelosBio is competing against.
  • AstraZeneca: Top-tier oncology pharma with a deep ADC portfolio via the Daiichi Sankyo alliance (Enhertu, Datroway). Broad incumbent that competes with VelosBio's target indications and could be a potential strategic acquirer of ADC assets.
  • Gilead Sciences: Owns Trodelvy (sacituzumab govitecan) via its Immunomedics acquisition, anchoring a growing ADC franchise in oncology. Broad incumbent actively building ADC capability through M&A — a plausible acquirer profile for an ADC-focused biotech like VelosBio.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

VelosBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VelosBio leadership team

Management profile

Number of profiles

Profiles1 record

VelosBio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VelosBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VelosBio

What does VelosBio do?

VelosBio is a clinical-stage biopharmaceutical company developing novel antibody-drug conjugates (ADCs) for the treatment of haematological cancers. The company builds next-generation oncology therapeutics that combine tumour-targeting antibodies with cytotoxic payloads to selectively destroy cancer cells.

When was VelosBio founded?

VelosBio was founded in 2017. It employs 11 to 50 people.

Where is VelosBio based?

VelosBio is headquartered in San Diego, United States, in the North America region.

Who are VelosBio's main competitors?

Direct peers on record are ADC Therapeutics, ImmunoGen, Seagen, Mersana Therapeutics and Heidelberg Pharma. Emerging players are Pyxis Oncology and Bolt Biotherapeutics. Broad incumbents are Daiichi Sankyo, AstraZeneca and Gilead Sciences.

Does VelosBio have an API?

No public API is recorded for VelosBio.

What industry is VelosBio in?

VelosBio's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
San Diego Business JournalMerck Buys VelosBio for $2.75 BillionMerck agreed to pay $2.75 billion for VelosBio, a biotech developing ROR1-targeted cancer therapies, with the deal expected to close by year-end. The acquisition adds VLS-101, an antibody-drug conjugate in Phase I and II trials, to Merck's oncology pipeline. The company has raised over $200 million since 2017.Barron'sMerck Just Bet Billions on Antibody-Drug Cancer Combos. Here’s Why.Merck announced a $2.75 billion cash acquisition of VelosBio, a privately held company. The deal adds another antibody-drug conjugate to Merck's portfolio, which targets cancer cells while sparing patients from many side effects.YahooMerck to bolster cancer drug portfolio with VelosBio $2.75 billion dealMerck agreed to acquire privately held VelosBio for $2.75 billion in cash, strengthening its cancer drug portfolio. The deal is expected to close by the end of the year, following Merck's September purchase of a Seattle Genetics stake.BioWorldFor $2.75B in cash, Merck set to acquire VelosbioMerck agreed to acquire Velosbio for $2.75 billion in cash, targeting Velosbio's ROR1-based cancer therapies. The deal is expected to close by end of 2020, with Velosbio's lead candidate VLS-101 in phase I and phase II studies. Velosbio's parent Arix expects $185 million net proceeds.VC News DailyVelosBio Raises $137M in Series BVelosBio, a clinical-stage biopharmaceutical company based in San Diego, completed an oversubscribed Series B financing of $137 million led by Matrix Capital Management and Surveyor Capital. The proceeds will advance clinical development of the company's lead antibody-drug conjugate VLS-101, a ROR1-targeted therapy currently in Phase 1 trials for hematologic cancers, with studies in solid tumors planned. The financing brings the company's total raised since its 2017 founding to $202 million.WsjVelosBio Raises $137 Million Series B Round for Cancer Drug DevelopmentVelosBio Inc. raised $137 million in a Series B round. CEO David Johnson previously led Acerta Pharma, which was acquired by AstraZeneca in 2016 for up to $7 billion. The funding supports cancer drug development.socaltech.comVelosBio Finds $137M For Oncology EffortsVelosBio raised $137M in a Series B funding round led by Matrix Capital and Surveyor Capital. The San Diego-based biopharmaceuticals developer will use the funds for its oncology efforts. The round also included Adage Capital Management LP, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, and OrbiMe.MedCity NewsVelosBio raises $58M in Series A round for antibody-drug conjugate developmentVelosBio raised $58 million in a Series A round led by Arix Bioscience and Sofinnova Ventures. Arix invested $11 million for an 11.2% stake. The company is developing antibody-drug conjugates for hematological cancers and solid tumors.socaltech.comVelosBio Finds $58MVelosBio, a San Diego biotech developing antibody-drug conjugates for hematological cancers and solid tumors, raised $58M in a Series A round led by Arix Bioscience. The round also included Pappas Ventures, Chiesi Ventures, Takeda Ventures, and Decheng Capital. The funding will be used for further development.